All In Biotech

Drug Trial Radar · NCT03831880

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL, CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF WEEKLY GROWTH HORMONE (SOMATROGON) VERSUS DAILY GROWTH HORMONE (GENOTROPIN (REGISTERED)) INJECTIONS IN CHILDREN WITH GROWTH HORMONE DEFICIENCY

Last checked: Nov 20, 2026Latest source record: Oct 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

87

Actual

Start

Feb 7, 2019

Primary completion

Aug 28, 2020

Study completion Aug 28, 2020

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label randomized 24 week crossover trial assessing the treatment burden of a weekly growth hormone injection regimen (somatrogon) compared to a daily growth hormone injection regimen (Genotropin). Approximately 90 children with growth hormone deficiency who have been stable on treatment with daily Genotropin will be enrolled.

Conditions

  • Growth Hormone Deficiency

Interventions

  • GenotropinDrug

    Genotropin (dose \[mg\] at time of enrollment) given subcutaneously once daily

  • somatrogonDrug

    0.66 mg/kg/week given subcutaneously once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) QuestionnaireTime frame: Baseline
  2. Total Score Related to Overall Life Interference Assessed at Week 12, Using DCOA 1 QuestionnaireTime frame: Week 12
  3. Total Score Related to Overall Life Interference Assessed at Week 24, Using DCOA 1 QuestionnaireTime frame: Week 24
  4. Total Score Related to Overall Life Interference by Treatment in Overall Study, Using DCOA 1 QuestionnaireTime frame: Baseline up to Week 24

Locations

32 sites in 5 countries. Site status is shown where the registry gives one.

  • Center of Excellence in Diabetes and Endocrinology

    Sacramento, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Rocky Mountain Pediatric Endocrinology

    Centennial, Colorado

  • Pediatric Endocrine Associates, PC

    Greenwood Village, Colorado

  • Nemours Children's Health System

    Jacksonville, Florida

  • Nemours Children's Specialty Care

    Jacksonville, Florida

  • Nemours Biomedical Research

    Orlando, Florida

  • Nemours Children's Hospital

    Orlando, Florida

  • Nemours Children's Clinic

    Pensacola, Florida

  • Shriners Hospitals for Children

    Tampa, Florida

  • Emory Children's Center

    Atlanta, Georgia

  • IU Health Pharmacy

    Indianapolis, Indiana

  • Riley Hospital for Children

    Indianapolis, Indiana

  • Children's Mercy Hospital and Clinics

    Kansas City, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

  • MultiCare Health System - Mary Bridge Children's Health Center

    Tacoma, Washington

  • MultiCare Institute for Research & Innovation

    Tacoma, Washington

  • First Pediatric Clinic UMHAT "St. Marina" EAD

    Varna, Bulgaria

  • Fakultni nemocnice Brno, Pediatricka Klinika

    Brno, Czechia

  • Nemocnicni lekarna FN Brno

    Brno, Czechia

  • Fakultni nemocnice v Motole, Pediatricka klinika 2.LF UK a FN Motol

    Prague, Czechia

  • Nemocnicni lekarna FN Motol

    Prague, Czechia

  • Nemocnicna Lekaren Nudch

    Bratislava, Slovakia

  • Národný ústav detských chorôb, Detská klinika

    Bratislava, Slovakia

  • Detská fakultná nemocnica Košice Klinika detí a dorastu LF UPJŠ a DFN

    Košice, Slovakia

  • Nemocnica lekaren DFN Kosice, Klinika deti a dorastu

    Košice, Slovakia

  • St. Georges University Hospitals NHS Foundation Trust

    London, United Kingdom

  • St. Georges University Hospital NHS Foundation Trust

    London, United Kingdom

  • The Institute of Child Health, University College London

    London, United Kingdom

  • Great Ormond Street Hospital

    London, United Kingdom

  • NIHR Clinical Research Facility, Great Ormond Street Hospital for Children NHS Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.